APL-1401是公司通过自主研究并发现其全新作用机制用于治疗自身免疫疾病的口服创新药物。目前该 在研产品尚处于临床试验早期阶段，未来临床试验结果能否支持药品递交上市申请、能否最终获得上市 批准以及何时获批均具有不确定性。 人民财讯12月3日电，亚虹医药(688176)12月3日公告，近日，公司开展的APL-1401用于治疗中重度活动 性溃疡性结肠炎的Ⅰb期临床试验结果入选第19届欧洲结直肠大会，并以壁报形式发布该研究的临床数 据。 ...

Group 1 - The core point of the article highlights that Yahui Pharmaceutical (688176.SH) is currently trading at 9.95 yuan, reflecting a decline of 2.26% and is in a state of share price decline since its IPO [1] - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at a price of 22.98 yuan per share, underwritten by CITIC Securities [1] - The stock price fell below the IPO price on the first trading day, reaching a maximum price of 20.00 yuan, which was the highest price since its listing [1] Group 2 - The total funds raised from the initial public offering (IPO) amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs, exceeding the original plan by 311 million yuan [1] - The funds are intended for projects including drug and medical device production, new drug research and development, marketing network construction, and working capital supplementation [1] - The total issuance costs for the IPO were 147 million yuan, with CITIC Securities receiving 130 million yuan in underwriting and sponsorship fees [1] Group 3 - The controlling shareholder and actual controller of Yahui Pharmaceutical is PAN KE, who holds American nationality and serves as the chairman and general manager of the company [1]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-044 江苏亚虹医药科技股份有限公司 关于变更签字注册会计师的公告 二、本次变更人员的基本信息、诚信记录和独立性情况 1、基本信息 1 王子竹女士，于 2022 年成为注册会计师，2017 年开始从事上市公司审计， 2017 年开始在立信会计师事务所执业，2025 年开始为公司提供审计服务。王子 竹女士近三年从业情况如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）已分别于 2025 年 4 月 18 日召开第二届董事会第十四次会议、2025 年 5 月 23 日召开 2024 年年度股 东大会，审议通过了《关于续聘公司 2025 年度审计机构的议案》，同意续聘立 信会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"）担任公司 2025 年度审计机构，具体内容详见公司分别于 2025 年 4 月 19 日、2025 年 5 月 24 日在上海证券交易所网站（www.sse.com.cn）披露的《江苏 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-043 一、说明会类型 本次投资者说明会以视频结合网络互动的方式召开，公司将针对 2025 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 1 会议召开时间：2025 年 11 月 27 日（星期四）13:00-14:45 会议召开地点：上海证券交易所上证路演中心 会议召开方式：上证路演中心视频结合网络互动 投资者可于 2025 年 11 月 20 日（星期四）至 11 月 26 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 securities@asieris.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 江苏亚虹医药科技股份有限公司 关于召开 2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 江苏亚 ...

Core Viewpoint - Yahui Pharmaceutical (688176) has seen a stock price increase of 4.31% this week, closing at 10.16 RMB as of November 14, 2025, with a total market capitalization of 5.803 billion RMB [1] Company Announcements - Yahui Pharmaceutical has completed a change in registered capital, with the new registered capital amounting to 571.170486 million RMB [1] - The company held a board and supervisory board meeting on August 28, 2025, and an extraordinary shareholders' meeting on September 23, 2025, where it approved the cancellation of the supervisory board, change in registered capital, and amendments to the company’s articles of association [1] - The company has received a new business license from the Taizhou Market Supervision Administration reflecting the changes in registered capital [1]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-042 江苏亚虹医药科技股份有限公司 关于完成注册资本变更并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日 召开第二届董事会第十八次会议、第二届监事会第十四次会议，于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会，审议通过了《关于取消监事会、变更注 册资本、修订<公司章程>并办理工商变更登记的议案》，同意公司取消监事会、 注册资本变更、修订《江苏亚虹医药科技股份有限公司章程》并办理工商变更登 记。具体内容详见公司分别于 2025 年 8 月 29 日、2025 年 9 月 24 日披露于上海 证券交易所网站（www.sse.com.cn）的《江苏亚虹医药科技股份有限公司关于取 消监事会、变更注册资本、修订<公司章程>并办理工商变更登记及修订、制定 公司部分治理制度的公告》（公告编号：2025-034）、《江苏亚虹医药科技股份有 限公司 ...

Core Insights - A new investment fund named Changzhou Liyang Qifan New Industry Investment Fund Partnership (Limited Partnership) has been established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes private equity investment, investment management, and asset management activities [1] - The fund is co-held by companies such as Yahu Pharmaceutical and Silergy Semiconductor Technology (Hangzhou) Co., Ltd [1]

Core Points - The stock price of Yahui Pharmaceutical (688176.SH) closed at 9.81 yuan, reflecting a decline of 1.6% and indicating a state of breaking issue [1] - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at a price of 22.98 yuan per share [1] - The stock experienced a break on its first trading day, with an intraday high of 20.00 yuan, which remains the highest price since its listing [1] Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 311 million yuan, with the company initially aiming to raise 2.070 billion yuan [1] - The total issuance costs for the IPO amounted to 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1] Project Allocation - The funds raised are intended for various projects, including drug and medical device production, new drug research and development, marketing network construction, and supplementing working capital [1] Company Leadership - The controlling shareholder, actual controller, chairman, and general manager of Yahui Pharmaceutical is PAN KE, who holds American nationality [1]

Core Viewpoint - Yahui Pharmaceutical, established in March 2010 and listed on the Shanghai Stock Exchange in January 2022, focuses on innovative drug development for urogenital tumors and other diseases, showcasing strong technical capabilities in R&D [1] Financial Performance - For Q3 2025, Yahui Pharmaceutical reported revenue of 216 million yuan, ranking 97th out of 110 in the industry, significantly lower than the top competitors, East China Pharmaceutical (32.664 billion yuan) and Fosun Pharmaceutical (29.393 billion yuan), and below the industry average of 280 million yuan and median of 83.8 million yuan [2] - The company incurred a net loss of 261 million yuan, ranking 106th out of 110, with a stark contrast to the leading companies, Heng Rui Medicine (5.76 billion yuan) and Fosun Pharmaceutical (3.056 billion yuan), and below the industry average of 299 million yuan and median of 78.29 million yuan [2] Financial Ratios - As of Q3 2025, Yahui Pharmaceutical's debt-to-asset ratio was 19.20%, an increase from 10.12% year-on-year, but still below the industry average of 35.26%, indicating relatively low debt pressure [3] - The gross profit margin for the same period was 74.76%, down from 79.44% year-on-year, yet higher than the industry average of 57.17%, suggesting a competitive edge in profitability [3] Executive Compensation - The chairman and general manager, Pan Ke, received a salary of 3.5808 million yuan in 2024, an increase of 168,400 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.06% to 25,200, while the average number of circulating A-shares held per shareholder increased by 16.41% to 17,300 [5] - The top ten circulating shareholders included Penghua Pharmaceutical Technology Stock A, which held 6.1424 million shares, a decrease of 401,700 shares from the previous period [5] Growth Prospects - According to Pacific Securities, Yahui Pharmaceutical's revenue grew by 62% year-on-year in the first half of 2025, primarily driven by the commercial success of its products, Pazopanib tablets and Naltrindole tablets [5] - The company has a strong cash reserve of approximately 1.825 billion yuan as of the end of Q2 2025, and its core product APL-1702 is progressing well towards approval, expected by the end of 2025 or early 2026 [5] - Southwest Securities noted that the company is focusing on deepening its product pipeline with self-developed small molecules and ADC innovative drugs, projecting revenues of 300 million, 500 million, and 740 million yuan for 2025, 2026, and 2027 respectively [6]

Core Viewpoint - The company, Jiangsu Yahon Pharmaceutical Technology Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, and confirming that there are no false records or misleading statements [2][3]. Financial Data Summary - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][8]. - The report includes major accounting data and financial indicators, with all figures presented in Renminbi [3][8]. - The company has a share repurchase account holding 8,667,675 shares, representing 1.52% of total shares [5]. Non-Recurring Gains and Losses - The report indicates that non-recurring gains and losses are applicable, but specific details on significant items are not provided [4]. Shareholder Information - The report does not include information on major shareholders or changes in shareholding due to securities lending [6][7].